Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib plus best supportive care vs placebo plus best supportive care in advanced hepatocellular carcinoma after failure of prior antiangiogenic therapy
2010-021590-37Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Axitinib plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Overall Survival. Started Oct 2010; status: completed.
02
Drugs
axitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2010-021590-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021590-37.